#BIOCEO18 “A Moment Decades in the Making”

It’s a first-of-its-kind gene therapy ever approved by the U.S. Food and Drug Administration, marking yet another critical milestone in the era of modern medicine. Known as Luxturna, the treatment was developed by Spark Therapeutics to tackle a rare genetic defect that leads to one devastating outcome: total blindness.
Jeffrey Marrazzo, Spark’s chief executive officer, noted that approval of Luxturna was a “moment decades in the making for the field of gene therapy, the inherit